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Abstract
Cataract is one of the most frequent visual impairment complications of uveitis, account-
ing for up to 40% of the visual loss seen in these patients. In general, uveitis patients differ 
from the general cataract population in that they are younger and have a higher rate of 
comorbidities, however the rates of inflammatory sequelae vary markedly among uveitic 
entities. Cataract development may be influenced by the cause and duration of uveitis, 
the degree of inflammation control, and the use of corticosteroid therapy. Cataract sur-
gery in patients with uveitis represents a serious challenge due to pre-existing ocular 
comorbidities that may limit the visual outcome and difficult the surgical procedure; the 
need for preoperative control of inflammation; and the efficacy of postoperative man-
agement to avoid immediate and late ocular complications. A detailed ophthalmologic 
exam prior to surgery is essential to know the status of pre-existing pathologic changes, 
adjust the medical therapy to achieve absolute control of inflammation, establish a sur-
gical plan, and deliver an objective visual prognosis to the patient or the relatives. The 
key point to surgical success is the absolute control of inflammation, meaning no cells in 
the anterior chamber for at least 3 months prior to surgery. Today, minimally invasive 
phacoemulsification with acrylic foldable intraocular lens implantation is the standard of 
care for most patients with uveitis. It must be taken into consideration that higher rates 
of intraoperative and postoperative complications may occur. Vision-limiting pathology 
related to pre-existing uveitis complications are the major contributing factors for limited 
postoperative visual outcome.
Keywords: uveitis, cataract, phacoemulsification, intraocular lens, steroids, macular 
edema, glaucoma
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1. Introduction
Cataract represents a significant burden in the management and visual outcome of uveitis 
patients. Up to 40% of the visual loss seen in these patients is either solely or largely due 
to cataract [1]. Lens opacification is caused by repeated episodes or sustained intraocular 
inflammation characterized by the release of free oxygen radicals, lysosomal enzymes, 
immune complex deposition on the lens capsule, hypoxia, and altered composition of the 
aqueous humor [2]. The development of cataract depends on the type of uveitis, the degree 
and duration of the inflammatory process, and on the prolonged and excessive use of corti-
costeroids [3–5].
Cataract surgery in patients with uveitis represents a serious challenge for the anterior seg-
ment surgeon [6, 7]. Nowadays, clear cornea phacoemulsification with intraocular lens (IOL) 
implantation is the standard of care for most patients with uveitis [8, 9]. However, despite 
remarkable progress on surgical techniques and IOL materials, certain specific considerations 
should be taken into account regarding patient selection, preoperative preparation, as well as 
perioperative and postoperative management for successful long-term results [10, 11]. Nearly 
one-third of all uveitic eyes have small pupils, which represent a surgical technical difficulty 
[2]. In such cases, higher rates of additional intraoperative maneuvers are required to obtain 
proper visualization and phacoemulsification of the cataract [4, 12, 13]. And, while surgery 
is associated with an improvement in best corrected visual acuity (BCVA), higher rates of 
both, intraoperative and postoperative complications have been reported [14, 15]. Moreover, 
it has been shown that the final BCVA in uveitic eyes is worse than in non-uveitic ones [14]. 
Therefore, identifying the cause of uveitis and pre-existing pathologic changes that affect the 
visual outcome, achieving absolute control of inflammation before surgery, careful surgical 
planning, and solving intraoperative and postoperative complications are crucial to obtain a 
successful result (BCVA ≥ 20/40).
2. Epidemiology
Cataract is the most common ocular complication in children with chronic uveitis with an 
estimated rate from 35 to 52.0% [16]. In juvenile idiopathic arthritis (JIA)-associated uve-
itis, the prevalence varies from 40 to 60% and the incidence of new-onset cataract formation 
has been estimated as 0.04/eye-year [17, 18]. On the other hand, in adult patients it is one of 
the most frequent complications of uveitis with a prevalence rate as high as 50% as seen in 
Fuchs uveitis [6, 14, 19, 20]. In HLA-B27-associated anterior uveitis, the most common cause 
of uveitis in adults, cataract formation is the third most frequent complication with an esti-
mated prevalence of 14%, and an incidence rate of 0.091 during follow-up time (Table 1) [21]. 
Cataract prevalence varies among different causes of uveitis and depends on multiple factors 
including etiology, localization of the inflammatory process, time elapsed between the onset 
and diagnosis of uveitis, the degree of inflammation, the clinical course, and the use of corti-
costeroids [1, 18, 22, 23].
Difficulties in Cataract Surgery
Cause of uveitis Cataract 
prevalence 
range (median)
Successful 
outcome 
BCVA 
≥ 20/40 
(Snellen)
Frequent complications References
Fuchs uveitis 15–75% (50%) 83% Intraoperative AC hemorrhage 
(3.6–76%)
Hyphema
Ocular hypertension (glaucoma) 
(3–35%)
PCO (14.6%)
Progressive vitreous opacification
[20, 27, 48, 49]
Herpetic uveitis 15–75% (24%) 72.2% Viral reactivation
Iris posterior synechiae
Secondary glaucoma
[63, 151–153]
Juvenile idiopathic 
arthritis-associated 
uveitis
40–60% (50%) 60–70% 
(67%)
Exuberant postoperative inflammation
Iris posterior synechiae
Secondary glaucoma (25%)
CME
Cyclitic membrane
Hypotony (Phthisis bulbi)
[4, 17, 18, 25, 26, 81, 
95, 97–99, 101, 110]
HLA-B27 
associated uveitis
9.2–20.1% NA Recurrent uveitis
CME
Iris synechiae
[21]
Pars planitis 36–42% (40%) 50–83% Persistent vitritis (haze)
CME (50%)
Glaucoma (10%)
PCO (10%)
IOL Cocooning (29%)
ERM
Optic nerve atrophy
[23, 28, 140, 154]
Adamantiades-
Behcet disease
21–26% (38.5%) 72.5% 
(42.4%)
Exuberant inflammation (12.5%)
Iris posterior synechiae (17.5%)
CME (12.5%)
ERM (7.5%)
Papillitis (optic nerve atrophy) (5%)
PCO (37.5% most common)
[148, 155, 156]
Vogt-Koyanagi-
Harada disease
10–35% 68% Exuberant inflammation
Iris anterior and posterior synechiae
Pupillary membrane
PCO (76%)
Macular scarring
[135, 157]
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3. Clinical characteristics of diverse forms of uveitis
In general, the uveitic population differs from the general population suffering from cataract 
in that they are younger and have a higher rate of comorbidities [15]. However, the rates of 
inflammatory sequelae vary markedly among uveitic entities [7, 24]. For this reason, each uve-
itis syndrome must be analyzed separately with respect to ocular complications and visual 
outcome [6, 14] (Table 1). While Fuchs uveitis regularly has the best visual prognosis and the 
least postoperative complications, JIA-associated uveitis has one of the most fear prognosis 
due to frequent pre-existing pathology, difficulties in reaching absolute control of inflamma-
tion, and multiple intraoperative and postoperative complications [4, 25–27].
4. Preoperative evaluation
A correct classification and etiologic diagnosis of the uveitic entity is very helpful to estab-
lish the appropriate surgical strategy and to determine the prognosis [8]. Moreover, a com-
plete preoperative ophthalmologic examination is essential since pre-existing pathology will 
have significant therapeutic and prognostic visual implications [16, 28]. For instance, corneal 
opacity, vitreous haze, macular edema, and optic nerve atrophy usually result in a poor 
visual outcome [6, 19]. Therefore, it is very important that the patient and/or their relatives 
have an objective report on the status of the eye to be operated in order to have a realistic 
expectation of the final visual result. Ancillary diagnostic tests are always necessary to detect 
pre-existing pathologic changes that will allow us to render a more accurate visual progno-
sis. In most cases, it is helpful to perform a macular function test. Several methods are avail-
able for this purpose including the potential acuity meter (PAM), the laser interferometer 
(LI), and the focal electroretinogram (fERG) [29, 30]. The PAM test has proven an accuracy 
of 84% in patients with poor visual acuity (<20/40) [30]. On the other hand, LI has shown a 
Cause of uveitis Cataract 
prevalence 
range (median)
Successful 
outcome 
BCVA 
≥ 20/40 
(Snellen)
Frequent complications References
Sympathetic 
ophthalmia
31.8% 67.79% 
(72.2%)
PCO (77.7%)
Glaucoma
[158]
Sarcoidosis 21% 61% PCO (57.1%)
Recurrent uveitis
CME
Glaucoma
[159]
AC = anterior chamber; PCO = posterior capsule opacification; CME = cystoid macular edema; ERM = epiretinal 
membrane.
Table 1. Prevalence, visual outcome, and complications of cataract surgery in uveitis.
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lower accuracy (65%) and a tendency for over-predicting vision compared to the PAM in 
these patients [29, 30]. Focal cone ERG is very sensitive for detecting macular pathology, 
showing 91% accuracy in eyes with poor visual acuity [30].
Linear A-B ultrasound is necessary to identify vitreous hemorrhage and opacity, as well as 
posterior segment changes like, retinal detachment, optic nerve swelling, and sclerochoroi-
dal thickness [31]. Another very useful device is high-frequency ultrabiomicroscopy (UBM), 
which generates high-resolution images at an almost histological level. In vivo image sec-
tions may be obtained up to 3–6 mm in depth, permitting visualization of anterior segment 
structures [32]. Frequent indications for UBM in uveitis include uveitis-glaucoma-hyphema 
syndrome (UGH), sclerouveitis, herpetic anterior uveitis, pars planitis, pseudophakic uveitis, 
hypotony, peripheral toxocariasis, and ciliary body pathology [32, 33].
Retina fluorescein angiography (FA) allows the detection of many different forms of posterior 
segment inflammatory changes. It is used to evaluate the activity and extent of chorioreti-
nitis and optic nerve involvement; identify macular edema and choroidal neovasculariza-
tion; diagnose certain posterior uveitic entities with typical features; evaluate retinal vascular 
involvement and neovascularization; and to monitor the therapeutic response [34]. However, 
many inflammatory changes occur in the peripheral retina where visualization may be dif-
ficult with conventional angiography. Wide field scanning laser ophthalmoscopy performs 
ultra-wide angle FA allowing clear identification of peripheral lesions and accurate docu-
mentation of disease progression [35]. This recently new image technology has replaced con-
ventional angiography for the diagnosis and monitoring of intermediate and many forms of 
posterior uveitis [35].
Indocyanine green angiography (ICGA) allows the detection of choroidal inflammation. Two 
patterns of choroidal vasculitis have been described: primary inflammatory choriocapilla-
ropathy and stromal inflammatory vasculopathy [36]. The first pattern is characterized by 
non-perfusion of the choriocapillaris found in entities like, multiple evanescent white dot syn-
drome, acute posterior multifocal placoid pigment epitheliopathy, multifocal choroiditis, and 
serpiginous choroidopathy [36]. The choroidal stromal inflammatory vasculopathy pattern 
is seen in active Vogt-Koyanagi-Harada disease (VKH), ocular sarcoidosis, tuberculosis, and 
birdshot chorioretinopathy [37]. In Behcet’s disease, as in other forms of uveitis, both ICGA 
vascular patterns may be seen at different stages of inflammation [38].
Today, the most frequently used imaging technique to detect and monitor macular inflamma-
tory changes is optical coherence tomography (OCT). With an axial resolution in the 5–7 μm 
range, it provides close to an in-vivo histologic view of the retina [39]. There are several types 
of OCT available for clinical purposes. The spectral-domain OCT is the most used method 
[40]. It allows high-speed, accurate images of the retina, particularly macular pathology like, 
cystoid and diffuse macular edema, subretinal fluid accumulation, epiretinal membrane for-
mation, macular holes, and choroidal neovascularization [41]. Longer wavelength OCT sys-
tems, including the swept-source technology and en-face imaging, enhance the detection of 
subtle microstructural changes in chorioretinal disorders by improving imaging of the choroid 
[42–44]. A technique that produces high-resolution cross-sectional images of the entire cho-
roid called enhanced depth imaging technique (EDI-OCT) has identified increased subfoveal 
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choroidal thickness in patients with active Behcet [45] and VKH disease, as well as loss of 
focal hyperreflectivity of the inner choroid in the acute and convalescent phases of VKH [46].
Once the preoperative evaluation is completed, a postoperative visual prognosis may be 
assumed, therapeutic adjustments may be applied, and a surgical plan is prepared based on 
pre-existing pathologic findings.
5. Preoperative preparation and therapeutic strategies
The key to surgical success in patients with uveitic cataract is the absolute control of inflam-
mation, meaning no cells in the anterior chamber for at least 3 months prior to surgery [7]. 
This requisite is crucial to obtain an optimal surgical result and to minimize postoperative 
complications [7, 24]. Active uveitis at the time of cataract surgery has been associated with 
worse visual outcomes [15, 47]. Moreover, postoperative cystoid macular edema (CME) is 
more likely to develop in eyes with active inflammation within a 3-month period before sur-
gery (relative risk 6.19) than those under control [41]. However, this general consensus of no 
cells in the anterior chamber prior to surgery has its exemptions [2]. In Fuchs uveitis, minimal 
but persistent anterior chamber cells and flare are frequently found despite intensive and 
sustained treatment with topical corticosteroids [48]. Hence, anti-inflammatory treatment is 
not indicated for the low-grade anterior chamber reaction seen in Fuchs uveitis and only 
occasionally, a short-course of corticosteroids is indicated for symptomatic exacerbations [49]. 
Other exemptions are related to the necessity for prompt surgical intervention in cases like, 
lens-induced uveitis, cyclitic membrane formation with hypotony, persistent vitreous opacity 
or hemorrhage, and retinal detachment [50, 51].
Preoperative management depends specifically on the type and etiology of uveitis. For inac-
tive idiopathic anterior non-granulomatous uveitis as for Fuchs uveitis, topical administra-
tion of prednisolone acetate 1% four times a day, starting 3–7 days before surgery may be 
sufficient to avoid an outburst of postoperative inflammation [24]. On the contrary, patients 
with JIA-associated uveitis, anterior granulomatous uveitis, intermediate, posterior, and 
panuveitis also require oral prednisone (1.0 mg/kg/day) starting 3 days before surgery and 
continued for a week after cataract removal and then tapered slowly according to the inflam-
matory status [52, 53]. Preoperative oral steroids have been shown to be effective in reducing 
the risk of CME [41]. If patients are on immunosuppressive chemotherapy and/or biolog-
ics, they should be continued at current dosage [11]. In case that systemic corticosteroids 
are contraindicated (e.g., diabetes mellitus, metabolic disease, acid-peptic disease, obesity, 
or osteoporosis), periocular administration (transseptal or sub-Tenon’s) of triamcinolone ace-
tonide (40 mg/ml) should be considered [54, 55]. Alternative immunosuppressive agents like, 
cyclosporin-A, tacrolimus, or anti-metabolites may be administered to these patients consid-
ering that most of these medications require a longer period of time (usually 4–6 weeks) to 
reach an optimal therapeutic effect [56].
The use of topical non-steroidal anti-inflammatory drugs (NSAIDs) like, ketorolac 0.4%, nepaf-
enac 0.15%, or bromfenac 0.09%, have become a standard of care practice for the perioperative 
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management of inflammation, pain, surgical-induced miosis, and cystoid macular edema in 
uneventful and also in uveitic cataract surgery [57–59]. A systematic review found high-quality 
evidence that topical NSAIDs are more effective than topical steroids in preventing the short-
term pseudophakic CME in non-uveitic cataract surgery [60]. On the other hand, a recent evi-
dence-based review conducted by the American Academy of Ophthalmology found that the 
claimed made about the synergistic effect of combined topical steroids and NSAIDs remains 
unproven [61]. In addition, NSAIDs have only a short-term therapeutic effect on prompt visual 
recovery and reduction of established CME, but no effect on the long-term visual outcome 
[57, 58, 61]. There is good collective clinical evidence and rationale that the application of a 
topical NSAID 3 days before surgery reduces CME and improves vision in the short-term [61]. 
Because the COX-2 enzyme is inducible and mostly responsible for the inflammatory process, 
the selective inhibitory effect of nepafenac and bromfenac makes them more suitable for this 
purpose [62]. Nepafenac has shown the shortest time to reach maximal concentration and the 
greatest aqueous humor peak concentration compared to ketorolac and bromfenac in eyes hav-
ing cataract surgery [62]. After the surgical procedure, topical NSAIDs use is usually extended 
for 4–6 weeks [1, 10].
There are other special conditions in uveitis in which certain specific actions should be taken 
before cataract extraction is performed. Such is the case of herpetic uveitis in which prophy-
lactic anti-viral therapy with acyclovir or valacyclovir should be administered at least 1 week 
before surgery in order to avoid recurrent viral infection [63, 64]. Other special consideration 
is the preoperative management of prominent band keratopathy interfering with cataract 
visualization which may be treated with EDTA 1–2% calcium chelation, or Excimer laser PTK 
before cataract surgery [65, 66].
Cataract and glaucoma frequently coexist as uveitis complications, and a combined surgical 
procedure may be associated with an increased risk of glaucoma surgery failure [67, 68]. In 
such cases, it may result better to perform a clear cornea small-incision cataract extraction first, 
followed later on by filtration surgery or a valve implantation with anti-metabolites [69, 70]. 
One must consider that uveitic glaucoma eyes operated for trabeculectomy with mitomycin-C 
which had previous cataract surgery or granulomatous uveitis, have a higher risk of surgical 
failure (RR = 2.957, P = 0.0344, and RR = 3.805, P = 0.0106, respectively) [71]. A higher risk of 
glaucoma surgical failure has also been associated with idiopathic, intermediate, and Fuchs 
uveitis; active intraocular inflammation at the time of surgery; and relapse of uveitis [72]. 
Moreover, the success rate of filtration surgery in uveitic eyes is significantly lower than that of 
non-uveitic, and many patients with successful intraocular pressure (IOP) control still require 
anti-glaucoma therapy to maintain adequate IOP levels in the postoperative period [72].
Posterior vitrectomy and cataract extraction may be an alternative for patients with promi-
nent posterior segment pathology including vitreous opacity, hemorrhage, cystoid macular 
edema, and tractional retinal detachment [73]. There is reasonable evidence that cataract 
phacoemulsification combined with posterior vitrectomy has a favorable visual outcome for 
some patients with refractory inflammation, particularly those with significant vitreous opac-
ity and chronic macular edema [13, 74]. In children, this combined surgical approach has 
been used for JIA-associated uveitis, pars planitis, and other forms of posterior uveitis [75]. 
Cataract Surgery in Patients with Uveitis: Preoperative and Surgical Considerations
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However, this technique is not exempt of serious postoperative complications like, glaucoma, 
macular edema, and exuberant inflammation [75, 76]. For specific cases with various ocular 
complications, multiple combined surgical strategies have been postulated including phaco-
emulsification with IOL implantation, posterior vitrectomy, intravitreal sustained-release cor-
ticosteroid injection, and glaucoma tube implantation with promising results [77].
6. Surgical technique and intraoperative maneuvers
Nowadays, small clear corneal incision phacoemulsification surgery is preferred over extra-
capsular cataract extraction (ECCE) and lensectomy for most patients with uveitis [78, 79]. 
Since cataract surgery in these patients is frequently complicated by corneal opacification, iris 
synechiae, pupillary and cyclitic membranes, among others, the surgical technique should 
be minimally invasive with precise and delicate maneuvers [10, 24] (Figure 1). Most studies 
report a higher rate of additional maneuvers, notably iris and pupillary manipulation within 
a range between 19 and 67% of eyes [4–6, 25].
Dealing with unexpected intraoperative complications like, corneal stromal edema; ante-
rior chamber hemorrhage; pigment dispersion; posterior capsule rupture with vitreous 
exposure is key to achieve the best surgical outcome possible [6, 19, 75]. The first chal-
lenge that the surgeon faces is an adequate exposure and visualization of the cataract. Iris 
synechiolysis, pupillary membrane removal, and pupil distension with iris hooks or iris 
stretch devices are frequently required for proper cataract visualization [80, 81]. There 
is no general consensus on what is the best way to deal with the pathologic changes of 
the anterior segment encountered in uveitic eyes. However, it is generally agreed that 
Figure 1. Anterior segment appearance of a patient with Vogt-Koyanagi-Harada disease showing extensive peripheral 
anterior and posterior synechiae, shallow anterior chamber and a pupillary membrane in front of a secondary cataract.
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attempts should be made to minimize surgical maneuvers in order to lessen tissue manip-
ulation and trauma as possible [6, 24, 26].
The capsulorhexis should measure between 5 and 6 mm in diameter because smaller apertures 
are frequently associated with capsular phimosis and posterior iris synechiae to the anterior cap-
sule remnant [82–84] (Figure 2). On the other hand, larger diameter capsulorhexis may affect the 
IOL centration and stability [83]. The phacoemulsification technique may vary depending on the 
density and zonular status of the cataract, but an effort should be made to use the less ultrasound 
power and time possible, to perform vigorous cortical and posterior capsule cleaning, and to 
avoid posterior capsule rupture [11, 19]. Avoiding the latter is crucial to obtain a good postopera-
tive result, especially in chronic and recurrent uveitis like, herpetic uveitis, pars planitis, VKH 
disease, toxoplasmosis, among others [6, 24, 85]. In these cases, posterior capsule rupture with 
vitreous exposure may be a contraindication for IOL implantation due to a high probability of 
postoperative excessive and persistent inflammation [12, 86]. In uveitic eyes with encapsulated 
and subluxated IOLs with extensive fibrosis, IOL removal may be necessary at some point of 
the postoperative period to control severe inflammation and reduce its consequences [87–89]. 
For eyes with extensive membrane formation in the anterior vitreous, vitrectomy after perform-
ing a posterior central capsulorhexis must be considered [90].
Decision making regarding the type of IOL to be used; anterior or posterior chamber IOL 
implantation; possible IOL sulcus fixation; combined filtration surgery, MIGS, or valve implan-
tation; central posterior capsulorhexis after PC-IOL implantation with anterior vitrectomy; 
lensectomy, as well as posterior vitrectomy with or without retinal surgery are frequently met 
during uveitic cataract surgery, and the surgeon must be prepared to make the best decision 
for the particular case [91–94]. The implantation of a foldable IOL “in the bag” is ideal for most 
cases of uveitis with certain exceptions [4, 95]. Until now, it is not clear how to proceed in chil-
dren with uveitic cataract, and randomized controlled trials (RCT) are necessary to  elucidate 
Figure 2. Patient with ankylosing spondylitis and HLA-B27-associated uveitis after cataract surgery showing capsular 
phimosis and partial adherence of the pigmentary epithelium of the iris to the anterior capsule remnant.
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this matter [4, 25, 26, 81]. Historically, uveitic cataract surgery during childhood has been 
associated with a higher rate of surgical complications, particularly excessive postoperative 
inflammation [6, 10]. In the past, this situation made that the preferred surgical techniques 
for cataract extraction in this group including ECCE with posterior pars plana vitrectomy or 
lensectomy [4, 95]. However, recent evidence favors the implantation of foldable PC-IOLs in 
children with uveitis, including patients with JIA-associated iridocyclitis [25, 26, 96–101].
Intraocular corticosteroids can be administered during surgery. Intracameral dexametha-
sone phosphate (400 μg/0.1 ml) or intravitreal triamcinolone (4 mg/0.1 ml) injection (IVTA) 
may be administered intraoperatively, except in advanced secondary glaucoma or known 
steroid-responsive patients [4, 102]. A prospective and comparative RCT between oral corti-
costeroids and preservative-free IVTA injection showed no differences in postoperative ante-
rior chamber reaction, IOP levels, and central macular thickness (CMT) [103]. Another study 
found a better effect of IVTA versus orbital floor TA on macular edema and postoperative 
inflammation after cataract surgery in patients with uveitis [55]. However, IVTA injections 
have a temporary effect therefore, may require repeated injections which are not exempt of 
serious ocular complications like, elevated IOP (30–43% eyes), bacterial endophthalmitis, 
vitreous hemorrhage, and retinal detachment [104]. For those eyes at higher risk for intravit-
real injection, sub-Tenon’s or transseptal TA can be administered at the end of surgery [19].
Intravitreal steroid sustained-release devices containing fluocinolone acetonide 0.59 mg or 
dexamethasone phosphate 0.7 mg have proven to be beneficial for the control of inflamma-
tion, prevention of CME, or reduction of CMT if applied a few days to weeks before or during 
cataract surgery [105]. Although no general consensus exists on the appropriate surgical time, 
it seems reasonable to perform the cataract surgery within 4–6 weeks from the last steroid 
implantation [105–107]. The most fear complication of sustained-release steroid devices is 
ocular hypertension (OHT). A meta-analysis found that 66% of eyes develop OHT after the 
implantation of the 0.59 mg fluocinolone acetonide device, compared to 32% following 4 mg 
IVTA, and only 15% with the 0.7 mg dexamethasone implant [108]. Risk factors for devel-
oping OHT include, pre-existing glaucoma, higher baseline IOP, younger age, OHT follow-
ing previous injection, uveitis, higher steroid dosage, and fluocinolone implant [108]. A new 
sustained-release implant containing 0.19 mg fluocinolone acetonide has shown promising 
results improving visual acuity and reducing CMT with a significant reduction of IOP com-
pared to the dexamethasone implant and IVTA [109].
7. Considerations for intraocular lenses
The general consensus regarding cataract surgery in patients with uveitis is that implanta-
tion of IOLs may be safely performed when ocular inflammation is completely abolished 
for a minimum period of 3 months [4, 7]. However, a debate still exists if an IOL should be 
implanted in specific circumstances like, lens-induced uveitis, JIA-associated iridocyclitis, 
young children with posterior or panuveitis, and intraoperative rupture of the posterior 
capsule with vitreous exposure [25, 26, 91, 110]. The implantation of an IOL triggers dif-
ferent intraocular responses including inflammation and foreign body reaction, as well as 
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activation of the complement and coagulation cascades [83, 111–113]. These reactions along 
with the breakdown of the blood-aqueous barrier induced by surgery may increase cellu-
lar adhesion and lens epithelial cell (LEC) proliferation on the anterior surface of the IOL, 
resulting in anterior capsule phimosis, fibrosis, and posterior capsule opacification (PCO) 
[114]. With the advent of technologic development, many advances have been made to 
reduce IOL-induced reactions and to improve their biocompatibility [115]. The inflamma-
tory response induced by IOLs is inversely related to its biocompatibility, so the higher the 
biocompatibility, the lower the inflammatory response [15, 83, 115]. Even though they were 
considered biologically inert, the first IOLs made of polymethyl-methacrylate (PMMA) 
were capable of producing foreign body reaction, as well as activate the complement and 
coagulation cascades [113, 116].
Different strategies have been used to reduce the host response, including the modification of 
the IOL surface by making it hydrophilic, like in heparin-coated PMMA IOLs, or hydropho-
bic such as surface passivated [83]. Heparin surface-modified IOLs have improved biocom-
patibility compared with unmodified PMMA IOLs in eyes at risk for severe postoperative 
inflammation, including those with uveitis [117, 118].
Foldable IOLs may be hydrophobic, including silicone IOLs or hydrophilic, and both surfaces 
have demonstrated to be relatively inert [114, 119]. Hydrophobic surfaces resist cell adhe-
sion while hydrophilic ones reduce electrostatic forces and cellular adhesion, preventing the 
attraction of inflammatory cells and their activation, as well as adherence of fibroblasts to the 
IOL surface [120, 121].
Anterior capsule phimosis has been related to the degree of fibrotic reaction produced by 
pro-inflammatory cytokines released by residual LEC [122, 123]. Careful vacuuming the 
undersurface of the anterior capsule helps to reduce the number of LEC [82, 124]. Capsular 
phimosis has been reported more frequently with hydrogel (poly-HEMA) than acrylic, and 
silicone IOLs [83, 125]. Foreign body giant cell precipitates are less frequently seen in hydro-
philic than on hydrophobic IOL surfaces and heparin-coated PMMA IOLs [115, 126]. The 
frequency of posterior capsule opacification (PCO) is highest with PMMA IOLs, less with 
silicone and minimal with acrylic IOLs [124, 127].
Few studies have evaluated the visual outcome following cataract surgery in uveitis with 
silicone IOL implantation. Overall, only 30% of eyes have achieved 20/40 of better vision with 
silicone IOLs, fewer than any other type of IOL [15]. Silicone was the first material avail-
able for foldable IOLs, but its use has declined particularly because it cannot be used for a 
monobloc open-loop designed, the preferred choice for preloaded injectors that allow implan-
tation through small corneal incisions [128].
With the advent of acrylic foldable IOLs, the biocompatibility issue has become a minor con-
cern, but controversy still exists of which material, hydrophilic or hydrophobic is best suit-
able for patients with uveitis [120, 126, 129]. Since the lens is surrounded by aqueous humor, 
it was thought that hydrophilic materials were more biocompatible than hydrophobic for 
patients with uveitis [89, 92]. However, there is insufficient evidence to determine the effects 
of different types of IOL materials, including hydrophobic and hydrophilic acrylic IOLs in 
patients with uveitis [129]. Results from the largest RCT provide only preliminary evidence 
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that acrylic IOLs may perform better than silicone IOLs in terms of improving vision and 
reducing the chances of postoperative inflammation and complications [129, 130]. A large 
multicenter RCT with standardized outcome measurements is necessary to properly address 
the surgical outcome of patients with uveitic cataract.
8. Immediate postoperative management
The postoperative management is as important as the preoperative preparation and the 
surgical procedure itself. Since the first postoperative moments, intense topical corticoste-
roids (1% prednisolone acetate hourly), topical NSAIDs (anti-COX-2 selective), topical wide 
spectrum antibiotics (fourth generation fluoroquinolones), overnight steroid ointment, as 
well as mydriatic-cycloplegic combinations (e.g., 1% tropicamide + 5% phenylephrine every 
6-hours × 5–7 days) should be administered [11, 24, 131]. Topical corticosteroids are wined 
down according to the grade of anterior chamber inflammatory reaction, the presence of 
glaucoma, or OHT in steroid-responders [54]. In case the patient was given systemic cor-
ticosteroids, they should be maintained at immunosuppressive levels (1 mg/kg/day) for 
7–10 days before reducing them slowly to a minimum dose of 7.5 mg/day [56]. In case the 
patient is on immunosuppressive chemotherapy or biologic therapy, it should be continued 
at maintenance dose [19, 131]. Systemic anti-virals used for herpetic uveitis should be kept 
at therapeutic dose for 7–14 days postoperative, and then reduced to prophylactic levels 
(acyclovir, 600–800 mg/day and valacyclovir 500–1000 mg/day) for several weeks to months 
before stopping them [63, 64, 132].
9. Postoperative complications and their management
Postoperative complications after cataract surgery in patients with uveitis are relatively fre-
quent [8]. The reported prevalence of complications is higher in ECCE than in phacoemul-
sification [78, 79, 133]. The risk for postoperative complications also depends on the type 
of uveitis and the degree of ocular involvement [8, 12, 85] (Table 1). Despite all preventive 
measurements taken before and during surgery, the most frequent and fear postoperative 
complication is the outburst of inflammation out of expected proportions [5]. Significant 
inflammation characterized by >2+ anterior chamber cells, extensive protein exudation with 
fibrin and plasmoid bodies formation, as well as fibrinoid membranes covering the pupil, and 
hypopyon may be seen [7, 19, 24, 134]. This aggressive inflammatory response is commonly 
associated with early postoperative iris synechiae formation and pupillary inflammatory 
membranes, particularly in disorders like JIA-associated uveitis, and VKH, among others [4, 
6, 131, 135]. The best way to deal with this unexpected postoperative inflammatory response 
consists on avoiding it by previous absolute control of inflammation and the implementation 
of perioperative measurements discussed before. Nevertheless, in those cases in which a sig-
nificant inflammatory reaction occurs, an adjustment to the systemic prednisone dose and the 
administration of atropine 1% will help to control the inflammation [52–54].
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Other immediate postoperative complications that may be seen are hyphema and significant 
pigment dispersion throughout the anterior segment [19, 24]. Pigment dispersion is related 
to a variety of factors including, surgical trauma, small pupil, and age [24, 83, 91]. In both 
cases, regular tonometry is mandatory for opportune detection of severe OHT related to 
clogging of the trabecular meshwork by ghost cells or pigment, respectively [6]. If anti-glau-
coma therapy is required, prostaglandin analogs as well as alpha-adrenergic drugs should 
be avoided as possible because they may exacerbate the inflammatory process [69]. In some 
patients with corneal stromal edema and Descemet folds due to high IOP, oral carbonic 
anhydrase inhibitors (e.g., acetazolamide 250 mg, 3–4 times a day) may be administered 
[69]. If the IOP becomes uncontrollable with medical therapy, filtration surgery or valve 
implantation should be considered to avoid further optic nerve damage [69, 136]. Finally, an 
excessive postoperative inflammatory process may produce significant vitreous opacity and 
membrane formation [5]. Once acute infectious endophthalmitis has been ruled out in such 
cases, aggressive anti-inflammatory therapy with systemic, periocular, and even intravitreal 
corticosteroids should be administered [52, 54, 55, 106]. If vitreous condensation and orga-
nization persist, a pars plana vitrectomy with or without intravitreal corticosteroid injection 
should be performed [13, 73, 75, 137].
In the late postoperative period, ocular complications are usually related with recurrent intra-
ocular inflammation occurring from 8.3 to 53% of cases [8, 12, 85, 133]. Recurrent postopera-
tive uveitis may produce anterior and/or posterior iris synechiae which may cause an angle 
or pupillary block glaucoma, respectively [69].
Certainly one of the most frequent ocular complications observed in this late period is pos-
terior capsule opacification seen in up to 58% of cases [82, 83, 85, 124, 133]. Nd-Yag laser 
capsulotomy usually resolves this problem, but in some cases retrolental hyaloid-vitreous 
opacification or significant deposition of pigment and inflammatory debris on the IOL surface 
may occur therefore, recurrent low-energy Nd-Yag laser and other operative procedures may 
be needed for polishing the IOL [82, 138]. It must be considered that Nd-Yag laser capsulot-
omy in patients with uveitis is associated with a higher risk for vision-threatening complica-
tions, including OHT, CME, IOL damage or luxation, as well as retinal detachment [40, 139].
Another very important visual-threatening postoperative complication is macular edema 
occurring from 33 to 56% after ECCE and from 12 to 59% after phacoemulsification [12, 85, 
133, 140]. The appearance of CME depends on multiple factors including the cause of uve-
itis and the type of surgical procedure performed [41]. Treatment of uveitic macular edema 
(UME) includes the administration of periocular injections of depot corticosteroids [54, 141]. 
However, as stated before, IVTA has shown to be superior to orbital floor injection for the 
treatment of UME [55, 142]. OHT is a potential complication of both types of steroid admin-
istration and should always be considered, particularly after repeated intravitreal injections 
[55, 108, 143]. Sustained-delivery corticosteroid devices may also be administered for this 
purpose [105, 106, 144]. In patients with bilateral UME, steroid-responders or those who do 
not accept periocular or intravitreal corticosteroid injections, oral prednisone along with oral 
carbonic anhydrase inhibitor (e.g., acetazolamide 250 mg every 12 hours) may be adminis-
tered [54]. Epiretinal membrane formation is more commonly seen in patients with chronic 
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UME with a prevalence ranging from 15 to 56% [12, 145, 146]. Treatment consists of pars plana 
vitrectomy and internal limiting membrane delamination [73, 146, 147].
Other less common, but serious complications is retinal detachment and hypotony [5, 26]. 
Hypotony may be related to the retinal detachment per se, or to a low aqueous humor pro-
duction due to inflammation of the ciliary process, or tractional detachment of the ciliary 
body due to cyclitic membrane formation [26]. Postoperative hypotony may evolve to pthisis 
bulbi [10, 88]. Both complications should be attended immediately by retinopexy, and/or pos-
terior vitrectomy with cyclitic membrane and sometimes intraocular lens removal, as well as 
peri- or intraocular corticosteroid administration [87, 88].
10. Prognosis and visual outcome
The outcome of cataract surgery in patients with uveitis is less predictable than in other 
causes of cataract. Many factors may contribute to this uncertainty including, pre-existing 
pathologic changes, intraoperative technical challenges, the impact of postoperative exuber-
ant inflammation, and the reversibility of postoperative complications derived from it [14]. 
Vision-limiting pathology related to pre-existing uveitis complications, especially macular 
edema and optic neuropathy are probably the major contributing factors for limited postop-
erative visual outcome [8, 15, 85].
Different studies suggest that visual prognosis varies according to uveitis subtypes [5, 
15, 26]. For instance, the proportion of eyes achieving 20/40 or better vision is better in 
Fuchs uveitis and worse in Behcet’s disease, VKH disease, or sympathetic ophthalmia [20, 
27, 47, 148]. In general, diseases that spare the posterior segment have a better prognosis 
than those affecting it, particularly macular and optic nerve involvement [5, 6, 8, 85]. In 
addition, acute uveitic entities tend to be associated with better outcome than chronic 
ones [12].
Uveitic cataract surgery has been associated with worse postoperative visual acuity, higher 
IOP, and more than double prevalence of UME when compared with non-uveitic cataract sur-
gery [14]. Moreover, the visual outcome following uveitic cataract extraction is not as good as 
that of age-related cataract surgery with the exception of Fuchs uveitis [27, 149]. Systematic 
reviews found a successful visual outcome (20/40 or better) in 96% of eyes with age-related cat-
aract surgery compared to 70% in uveitic eyes undergoing either phacoemulsification or ECCE 
[15, 149]. ECCE and phacoemulsification seem to have similar visual outcomes compared to 
half less successful rate after pars plana lensectomy [15]. With respect to the comparable visual 
results reported between ECCE and phacoemulsification, it must be taken into account that 
most ECCE trials have more exclusion criteria than phacoemulsification studies, favoring bet-
ter visual outcomes [15, 85, 150].
Finally, regarding IOL implantation, more eyes (71%) undergoing cataract surgery with IOL 
implantation than eyes left aphakic (52%) achieved a BCVA ≥ 20/40 vision postoperatively 
[14]. Eyes receiving acrylic IOLs or heparin surface-modified PMMA had better visual out-
comes than those receiving non-heparin-PMMA or silicone IOLs [14, 15, 83, 94].
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